Table III.
Univariate analysis of clinicopathological parameters for overall and progression-free survival in 126 breast ductal carcinoma patients.
| Overall survival time (months) | Progress-free survival time (months) | ||||
|---|---|---|---|---|---|
| Variable | Cases | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Age (year) | 126 | 0.502 | 0.982 | ||
| <48 | 62 | 1 | 1 | ||
| ≥48 | 64 | 1.270 (0.632–2.554) | 0.994 (0.594–1.664) | ||
| Histological grade | 0.093 | 0.130 | |||
| I | 17 | 1 | 1 | ||
| II | 79 | 2.211 (0.515–9.492) | 1.075 (0.475–2.430) | ||
| III | 30 | 4.164 (0.922–18.809) | 1.881 (0.785–4.509) | ||
| Tumor size | 0.158 | 0.535 | |||
| T2 | 99 | 1 | 1 | ||
| T3 | 27 | 1.742 (0.806–3.768) | 1.216 (0.656–2.255) | ||
| Lymph node metastasis | 0.964 | 0.702 | |||
| N0 | 42 | 1 | 1 | ||
| N1 | 37 | 0.842 (0.339–2.093) | 1.344 (0.710–2.543) | ||
| N2 | 24 | 1.018 (0.394–2.626) | 0.891 (0.411–1.932) | ||
| N3 | 23 | 1.099 (0.406–2.971) | 1.148 (0.530–2.489) | ||
| Distant metastasis | 0.017a | 0.010a | |||
| M0 | 118 | 1 | 1 | ||
| M1 | 8 | 3.618 (1.262–10.369) | 3.072 (1.313–7.185) | ||
| ER | 0.819 | 0.970 | |||
| Negative | 92 | 1 | 1 | ||
| Positive | 34 | 1.094 (0.506–2.365) | 0.989 (0.549–1.780) | ||
| PR | 0.384 | 0.766 | |||
| Negative | 89 | 1 | 1 | ||
| Positive | 37 | 0.701 (0.315–1.560) | 1.087 (0.628–1.882) | ||
| HER2 | 0.098 | 0.563 | |||
| Negative | 94 | 1 | 1 | ||
| Positive | 32 | 1.832 (0.895–3.747) | 1.185 (0.666–2.109) | ||
| Smad2 | 0.618 | 0.558 | |||
| Low | 60 | 1 | 1 | ||
| High | 66 | 0.838 (0.419–1.617) | 1.168 (0.695–1.965) | ||
| p-Smad2 | 0.187 | 0.070 | |||
| Negative | 25 | 1 | 1 | ||
| Positive | 101 | 0.595 (0.275–1.286) | 0.581 (0.322–1.046) | ||
| Smad4 | 0.051 | 0.040a | |||
| Negative | 21 | 1 | 1 | ||
| Positive | 105 | 0.465 (0.215–1.005) | 0.523 (0.282–0.971) | ||
a
P<0.05. Smad, SMAD family member; p-, phosphorylated; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; CI, confidence interval.